Dynamic Changes in Circulating Tumour Cells Protein Expression
NCT06314997
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
150
Enrollment
OTHER
Sponsor class
Conditions
Recurrence Free Survival
Interventions
DRUG:
panitumumab (EGFR inhibitors)
Sponsor
Matteo's Friends